Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829593 · ClinicalTrials.gov registry record · NA
Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA
A NA study of Healthy and Type 1 Diabetes, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT02829593: Completed NA study of Healthy and Type 1 Diabetes, sponsored by University of Minnesota.
NCT02829593 is a NA study of Healthy and Type 1 Diabetes that has completed, run by University of Minnesota. The registered enrollment target is 34 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02829593, a NA study of Healthy and Type 1 Diabetes, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
You are invited to participate in a study designed to investigate the effects of diabetes mellitus, high and low glucose, and high blood insulin on the brain. You were selected as a possible participant because you fit into one of the following categories. a) you are either healthy and competent, are not pregnant and you have no known medical disease and therefore your glucose metabolism will be typical of a normal person, or b) you have diabetes.
Primary Outcome
MRI measurement of GABA in the hypothalamus
Conditions Studied
Interventions
- OTHER hypoglycemia (low blood sugar) and MRI
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2023-05-31 |
| Phase | NA |
What the finished NCT02829593 record still lists
NCT02829593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which hypoglycemia (low blood sugar) and MRI is the first listed.
NCT02829593 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02829593 about?
NCT02829593 is a clinical study titled "Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA". You are invited to participate in a study designed to investigate the effects of diabetes mellitus, high and low glucose, and high blood insulin on the brain. You were selected as a possible participant because you fit into one of the following categories. a) you are either healthy and competent, ar...
What is the current status of trial NCT02829593?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2019-10-31. Estimated completion is 2023-05-31.
What conditions does trial NCT02829593 study?
This clinical trial studies the following conditions: Healthy, Type 1 Diabetes.
What interventions are being tested in trial NCT02829593?
The interventions under investigation include: hypoglycemia (low blood sugar) and MRI (OTHER).
Who is sponsoring clinical trial NCT02829593?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02829593 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02829593's enrollment target sits among peer trials
34 631st of 1090 higher than 451 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI